title: Reduced expression of β2 integrin genes in rat peripheral leukocytes by inhibiting postprandial hyperglycemia.
abstract: β(2) integrins (CD11s/CD18) promote the attachment of leukocytes to vascular endothelial cells. We performed in this study sucrose loading to rats with moderate postprandial hyperglycemia with/without once-daily dosing of the α-glucosidase inhibitor, miglitol, for 4 days under 4-h fasting conditions. The streptozotocin (STZ)-treated rats showed moderate postprandial hyperglycemia on days 1 and 4. The gene expression was higher for CD11a with fasting and 3-h postprandial on day 1, and with fasting on day 4, for CD11b with fasting on day 1 and 3-h postprandial on day 4, and for CD18 with fasting on days 1 and 4 in peripheral leukocytes from the STZ-treated rats than in peripheral leukocytes from the saline-treated rats. Miglitol reduced postprandial hyperglycemia and the gene expression of CD11a with fasting and of CD11b 3-h postprandial on day 4. These results indicate that inhibiting postprandial hyperglycemia reduced the mRNA expression of β(2) integrins in peripheral leukocytes of moderately postprandial hyperglycemic rats.
authors.affiliation: Laboratory of Nutritional Physiology, Graduate School of Nutritional and Environmental Sciences and Global COE Program, The University of Shizuoka, Shizuoka, Japan.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Mochizuki
authors.forename: Masaya
authors.initials: M
authors.lastname: Shimada
authors.forename: Yutaro
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Nanae
authors.initials: N
authors.lastname: Fukaya
authors.forename: Toshinao
authors.initials: T
authors.lastname: Goda
mesh_terms: D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D018821:CD18 Antigens / Q000235:genetics*; D004186:Disaccharidases / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005786:Gene Expression Regulation / Q000187:drug effects*; D065089:Glycoside Hydrolase Inhibitors; D006943:Hyperglycemia / Q000097:blood* / Q000188:drug therapy / Q000235:genetics*; D007421:Intestine, Small / Q000166:cytology; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D008871:Microvilli / Q000201:enzymology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D001786:Blood Glucose; D018821:CD18 Antigens; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; C045621:miglitol; D017485:1-Deoxynojirimycin; D004186:Disaccharidases